Show simple item record

Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer.

dc.contributor.authorPeeters, M*
dc.contributor.authorPrice, T*
dc.contributor.authorCervantes, A*
dc.contributor.authorSobrero, A*
dc.contributor.authorDucreux, M*
dc.contributor.authorHotko, Y*
dc.contributor.authorAndré, T*
dc.contributor.authorChan, E*
dc.contributor.authorLordick, F*
dc.contributor.authorPunt, C*
dc.contributor.authorStrickland, A*
dc.contributor.authorWilson, Gregory*
dc.contributor.authorCiuleanu, T*
dc.contributor.authorRoman, L*
dc.contributor.authorVan Cutsem, E*
dc.contributor.authorTian, Y*
dc.contributor.authorSidhu, R*
dc.date.accessioned2014-04-17T08:30:20Z
dc.date.available2014-04-17T08:30:20Z
dc.date.issued2014-01
dc.identifier.citationFinal results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer. 2014, 25 (1):107-16 Ann Oncolen
dc.identifier.issn1569-8041
dc.identifier.pmid24356622
dc.identifier.doi10.1093/annonc/mdt523
dc.identifier.urihttp://hdl.handle.net/10541/315912
dc.description.abstractThe study 20050181 demonstrated significant improvements in progression-free survival (PFS), objective response, and a nonsignificant trend toward increased overall survival (OS) with panitumumab-FOLFIRI versus FOLFIRI alone for second-line wild-type (WT) KRAS metastatic colorectal cancer (mCRC). Updated long-term data from a prespecified descriptive analysis are reported.
dc.language.isoenen
dc.rightsArchived with thanks to Annals of oncology : official journal of the European Society for Medical Oncology / ESMOen
dc.titleFinal results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer.en
dc.typeArticleen
dc.contributor.departmentDepartment of Oncology, University Hospital Antwerp, Antwerp, Belgiumen
dc.identifier.journalAnnals of Oncologyen
html.description.abstractThe study 20050181 demonstrated significant improvements in progression-free survival (PFS), objective response, and a nonsignificant trend toward increased overall survival (OS) with panitumumab-FOLFIRI versus FOLFIRI alone for second-line wild-type (WT) KRAS metastatic colorectal cancer (mCRC). Updated long-term data from a prespecified descriptive analysis are reported.


This item appears in the following Collection(s)

Show simple item record